Omalizumab : A therapeutic option in moderate to severe Asthma  

Oleh:

Wan-Peng, Lim ; Dessmon YH Tai

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Medical Progress vol. 34 no. 11 (Nov. 2007), page 549.

Ketersediaan

Perpustakaan FK Nomor Panggil: M36.K.2007.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Immunoglobulin E (IgE)- mediated responses to common aeroallergens predispose to the development of asthma. Subcutaneous omalizumab is an anti-immunoglobulin E monoclonal antibody which can be used in moderate to severe persistent asthma that is IgE-mediated. It has been shown to reduce the number of asthma wxacerbations, but its current role with respect to other standard modalities of treatment is unclear....

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali